Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To compare prevalence of pT3/T4 categories (in reference to UICC 2002 criteria, Appendix F) between subjects receiving panitumumab plus epirubicin, cisplatin and capecitabine (ECX) versus subjects treated with ECX chemotherapy alone.
Inclusion criteria
- Subjects with Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction